{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:19Z","timestamp":1787008699038,"version":"build-2736575974"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evolocumab, a fully humanized monoclonal antibody that inhibits proprotein convertase subtilisin\/kexin Type 9 (PCSK9), is one of the most widely used lipid-lowering therapies for atherosclerotic cardiovascular disease. It is generally well tolerated, but immune-mediated inflammatory reactions may occur with monoclonal antibodies. Among common adverse effects associated with evolocumab, pericardial disease associated with PCSK9 inhibitors is extremely rare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A man in his late 70s on evolocumab for 2 months presented to the hospital for atrial flutter and moderate pericardial effusion. He was treated with amiodarone and discharged with colchicine and indomethacin. Ten days later, the patient represented with worsening shortness of breath, malaise, and jugular venous distension with echocardiographic evidence of tamponade physiology. Emergent pericardiocentesis drained about 1\u2005L of sanguineous fluid. Autoimmune, infectious, and malignant aetiologies were systematically excluded. Evolocumab was discontinued, and the patient remained asymptomatic without recurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case illustrates a probable immune-mediated pericarditis with haemorrhagic effusion and tamponade seen with evolocumab use. Clinicians should remain vigilant for this rare monoclonal antibody\u2013associated pericardial inflammation as a potentially serious adverse reaction to evolocumab, particularly when other common causes have been excluded. Continued pharmacovigilance is essential as the use of PCSK9 inhibitors expands.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytag403","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:49:06Z","timestamp":1780055346000},"source":"Crossref","is-referenced-by-count":1,"title":["Evolocumab-associated haemorrhagic pericarditis with cardiac tamponade: case report"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-7981","authenticated-orcid":false,"given":"Aaron Y","family":"Kim","sequence":"first","affiliation":[{"name":"Internal Medicine, New York Presbyterian Brooklyn Methodist Hospital , Brooklyn, NY 11215 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bradel","sequence":"additional","affiliation":[{"name":"Cardiology, New York Presbyterian Brooklyn Methodist Hospital , Brooklyn, NY 11215 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimrah","family":"Hossain","sequence":"additional","affiliation":[{"name":"Cardiology, New York Presbyterian Brooklyn Methodist Hospital , Brooklyn, NY 11215 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Wong","sequence":"additional","affiliation":[{"name":"Cardiology, New York Presbyterian Brooklyn Methodist Hospital , Brooklyn, NY 11215 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026070815570920500_ytag403-B1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2026070815570920500_ytag403-B2","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070815570920500_ytag403-B3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jcph.832","article-title":"Evaluation of evolocumab (AMG 145), a fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment","volume":"57","author":"Gibbs","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026070815570920500_ytag403-B4","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1898831","article-title":"Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells","volume":"13","author":"Cohen","year":"2021","journal-title":"MAbs"},{"key":"2026070815570920500_ytag403-B5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/antib9040058","article-title":"The role of complement in the mechanism of action of therapeutic anti-cancer mAbs","volume":"9","author":"Golay","year":"2020","journal-title":"Antibodies (Basel)"},{"key":"2026070815570920500_ytag403-B6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"2026070815570920500_ytag403-B7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312640","article-title":"PCSK9 induces tissue factor expression by activation of TLR4\/NF-\u03baB signaling","volume":"22","author":"Scalise","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026070815570920500_ytag403-B8","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"2026070815570920500_ytag403-B9","doi-asserted-by":"crossref","first-page":"37112","DOI":"10.1038\/s41598-025-21064-9","article-title":"A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma","volume":"15","author":"Singh","year":"2025","journal-title":"Sci Rep"},{"key":"2026070815570920500_ytag403-B10","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/j.jacl.2024.04.034","article-title":"Pericardial and pleural effusions after evolocumab in a patient with severe familial hypercholesterolemia","volume":"18","author":"Pavlovic","year":"2024","journal-title":"J Clin Lipidol"},{"key":"2026070815570920500_ytag403-B11","article-title":"Life-threatening reaction to lifesaving medication: stepwise approach to severe adverse reactions to PCSK9 monoclonal antibodies","volume":"29","author":"Bimal","year":"2024","journal-title":"JACC Case Rep"},{"key":"2026070815570920500_ytag403-B12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/pharmaceutics15020323","article-title":"Inclisiran\u2014safety and effectiveness of small interfering RNA in inhibition of PCSK9","volume":"15","author":"Wo\u0142owiec","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026070815570920500_ytag403-B13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytag403\/68450505\/ytag403.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/7\/ytag403\/68450505\/ytag403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/10\/7\/ytag403\/68450505\/ytag403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T19:57:13Z","timestamp":1783540633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytag403\/8699880"}},"subtitle":[],"editor":[{"given":"Josip Andelo","family":"Borovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Giacomo","family":"Mugnai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Dzhem","family":"Farandzha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":13,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytag403","relation":{},"ISSN":["2514-2119"],"issn-type":[{"value":"2514-2119","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,6,2]]},"article-number":"ytag403"}}